News

LB Select
2025.11.06 08:56

AstraZeneca announced its third-quarter results, with total revenue increasing by 12% year-on-year to USD 15.191 billion, and core earnings per share of USD 2.38, exceeding market expectations of USD 2.27, benefiting from strong sales of key cancer and diabetes drugs. Revenue for the first nine months grew by 10% year-on-year to USD 43.236 billion, with core earnings per share of USD 7.04. The company reiterated that full-year revenue is expected to achieve high single-digit growth, and core earnings per share are expected to grow in the low double digits, which is broadly in line with market expectations. The company plans to announce a full-year dividend of USD 3.20 per share for 2025, up from USD 3.10 last year

Source: LB Select The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.